Context Therapeutics Inc.
CNTXContext Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for the treatment of solid tumors.
Table of contents
Earnings
Next report
Aug 5, 2026 (In 1 week)Competitors
By market cap
Profile
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for the treatment of solid tumors. The company leverages its expertise in antibody engineering to create therapies that redirect the immune system to target and eliminate malignant cells while sparing healthy tissue. Their core value proposition lies in advancing a pipeline of selective cancer therapies for patient populations with significant unmet medical needs.
A clinical-stage developer focused on bispecific antibodies for solid tumors, currently advancing multiple candidates through Phase 1 trials.
Questions, answered.
- What is Context Therapeutics Inc.'s market cap?
- Context Therapeutics Inc. (CNTX) has a market capitalization of $57.2M and trades on NASDAQ.
- Who are Context Therapeutics Inc.'s competitors?
- Context Therapeutics Inc.'s key competitors include Amgen Inc., ImmunityBio, Inc. Common Stock, CytomX Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Context Therapeutics Inc. partner with?
- Context Therapeutics Inc.'s notable partners include Australian Bellberry Human Research Ethics Committee, U.S. Food and Drug Administration.
- Where is Context Therapeutics Inc. headquartered?
- Context Therapeutics Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2021.